Detalhe da pesquisa
1.
High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.
Cancer Sci
; 114(2): 606-618, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36169649
2.
Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.
Oncologist
; 28(6): 551-e454, 2023 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37053467
3.
Pulmonary Pleomorphic Carcinoma Harboring EGFR Mutation Successfully Treated with Osimertinib: A Case Report.
Medicina (Kaunas)
; 58(6)2022 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35743969
4.
Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report.
Medicina (Kaunas)
; 57(6)2021 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34072448
5.
Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
Invest New Drugs
; 36(5): 903-910, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29846848
6.
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
Front Immunol
; 15: 1348034, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38464519
7.
Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study.
JTO Clin Res Rep
; 5(3): 100644, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38444594
8.
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.
Front Oncol
; 14: 1303543, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38344209
9.
Pseudoprogression during induction treatment with nivolumab plus ipilimumab combined with chemotherapy for metastatic lung adenocarcinoma: A case report.
Respirol Case Rep
; 11(4): e01122, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36926450
10.
Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study.
Cancers (Basel)
; 15(5)2023 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36900334
11.
Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study.
Cancers (Basel)
; 15(17)2023 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37686634
12.
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
JAMA Netw Open
; 6(7): e2322915, 2023 07 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37432682
13.
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.
NPJ Precis Oncol
; 7(1): 12, 2023 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36702855
14.
TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study.
JTO Clin Res Rep
; 4(4): 100494, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37020925
15.
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.
Target Oncol
; 18(6): 915-925, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37902896
16.
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
Cancers (Basel)
; 15(20)2023 Oct 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37894357
17.
Atezolizumab in combination with carboplatin plus nab-paclitaxel for managing combined large-cell neuroendocrine carcinoma: A case report.
Respirol Case Rep
; 10(7): e0989, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35685848
18.
Nasogastric administration of osimertinib suspension for an epidermal growth factor receptor-mutated lung cancer causing an esophageal stricture: case report.
Ann Palliat Med
; 11(4): 1542-1545, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34263613
19.
Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.
Cancer Med
; 11(4): 944-955, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35029047
20.
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.
NPJ Precis Oncol
; 6(1): 5, 2022 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35042943